[{"id":"111b005d-025a-47ec-8152-1a699a0603e5","acronym":"MK-2140-002","url":"https://clinicaltrials.gov/study/NCT04504916","created_at":"2021-12-21T18:53:50.313Z","updated_at":"2024-07-02T16:35:44.378Z","phase":"Phase 2","brief_title":"A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Solid Tumors (MK-2140-002)","source_id_and_acronym":"NCT04504916 - MK-2140-002","lead_sponsor":"VelosBio Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zilovertamab vedotin (MK-2140)"],"overall_status":"Completed","enrollment":" Enrollment 102","initiation":"Initiation: 10/07/2020","start_date":" 10/07/2020","primary_txt":" Primary completion: 06/12/2023","primary_completion_date":" 06/12/2023","study_txt":" Completion: 06/12/2023","study_completion_date":" 06/12/2023","last_update_posted":"2023-06-29"}]